Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
From IT Services to Enterprise AI: What ATGL Must Prove Next
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
From IT Services to Enterprise AI: What ATGL Must Prove Next
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
A-share Pre-market Briefing | Wu Qing Makes Major Remarks Over the Weekend! NVIDIA Corporation (NVDA.US) Set to Report Earnings Soon
Wu Qing: Deepen research on long-term mechanisms for market stability, assess institutional improvements including quantitative trading and share reductions.
23 m ago
Brokerage Morning Meeting Highlights | Institutional Stock Clearing Accelerates; Focus on the Main Line of Domestic Demand Policy
CITIC Securities believes that in this round of adjustment, the clearing of large institutional stocks has been much faster than in the past, while the slow clearing of small- and micro-cap stocks may have only just begun.
36 m ago
JUNSHI BIO (01877): Tuoyi New Indication Included in the National Medical Insurance Catalog
JUNSHI BIO (01877) announced that recently, the indication of the Company's product toripalimab injection (trade name: Tuoyi, product code: JS001) in combination with disitamab vedotin for HER2-expressing locally advanced or metastatic urothelial carcinoma was successfully included in the Class B scope of the "National Drug Catalog for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2026)" (hereinafter referred to as the "National Medical Insurance Catalog"). The new version of the National Medical Insurance Catalog will be officially implemented starting January 1, 2027.
50 m ago
ENVISION GREEN (01783) signs computing power service framework agreement, secures supply of over 30,000 GPUs; compliant computing power leasing logic strengthens, making the computing power leasing business more economical
Envision Green (01783) announced that on November 15, 2026, the Company signed a non-binding strategic cooperation framework agreement (the Strategic Cooperation Framework Agreement) with a leading artificial intelligence foundation model company (the AI Model Company) in respect of computing power services, pursuant to which both parties agreed to cooperate on the provision of computing power services by the Group to the AI Model Company (the Cooperation Matter).
1 h ago
GENFLEET-B(02595): Pan-RAS inhibitor GFH276 combination therapy study in pancreatic cancer completes first patient dosing in China and overseas; Phase II stage will include three first-line combination treatment regimens
GenFleet Therapeutics-B (02595) announced that the oral pan-RAS inhibitor GFH276 has entered an Ib/II phase multicenter, open-label combination therapy study, which will be conducted at dozens of research centers in China and Australia. The first overseas enrolled patient recently completed dosing at Monash Health in Australia, and the first enrolled patient in China completed dosing in the third quarter of this year at Fudan University Shanghai Cancer Center.
1 h ago
HK Stock Concept Tracker | 51 Class 1 innovative drugs included in the new national medical insurance drug list! Commercialization of innovative drugs accelerates (with concept stocks attached)
On November 14, at the 2026 Innovative Drug High-Quality Development Conference held in Suzhou, the adjustment results for the 2026 National Basic Medical Insurance Drug List and the Commercial Health Insurance Innovative Drug List were officially announced.
1 h ago
INNOVENT BIO (01801): Sintilimab ZYBRIVO receives positive CHMP opinion recommending approval for first-line treatment of non-squamous non-small cell lung cancer
Innovent Biologics (01801) announced that sintilimab (European trade name: Zybrivo) has received the first positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). The CHMP recommends approval of the marketing authorization for sintilimab in combination with chemotherapy for the treatment of adult patients with advanced non-squamous non-small cell lung cancer (NSCLC). If approved by the European Commission, Zybrivo will expand first-line treatment options for lung cancer patients in Europe. Sintilimab is an immunotherapy drug and a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to programmed cell death protein 1 (PD-1).
1 h ago
US "Vulcan" rocket launch fails, 40 Amazon.com, Inc. (AMZN.US) satellites destroyed, broadband network deployment faces obstacles.
The U.S. "Vulcan" rocket failed to send Amazon satellites into their intended orbit.
1 h ago
Morgan Stanley backs SpaceX (SPCX.US): stock price could double to $300, with enterprise AI as the largest source of valuation
Morgan Stanley analyst Adam Jonas reiterated on November 13 an "Overweight" rating and a $300 price target on SpaceX.
1 h ago
HK Stock Concept Tracker | Blizzards and Sharp Temperature Drops Hit in Succession! Peak Winter Coal-Use Season Heats Up as Coal Sector Welcomes Seasonal Catalyst (with Concept Stocks)
In mid-November, as a new round of cold waves hits in succession, many parts of China are experiencing large-scale temperature drops and rain and snow, and winter heating demand is expected to be released at an accelerated pace.
1 h ago
HK Stock Concept Tracker | "15th Five-Year Plan" New-Type Energy Storage Implementation Plan Issued, 2030 Installed Capacity Targets 300 Million Kilowatts (with Concept Stocks)
On November 13, the National Development and Reform Commission and the National Energy Administration issued the "15th Five-Year Plan" New-Type Energy Storage Implementation Plan.
1 h ago
AI trade faces a "week of reckoning"! Nvidia's earnings and Anthropic's listing will test the computing-power narrative, while "horror data" and retail stock earnings will test rate-hike expectations.
This week, Nvidia's earnings release and a potential Anthropic IPO could test the volatile AI trade.
1 h ago
YUK WING GP (01536) plans intelligent upgrades to existing group products.
YUK WING GP (01536) announced that the Company plans to carry out intelligent upgrades to existing Group products, and once artificial intelligence technology matures, it will extend the relevant technology to products in other fields. The Board intends to expand the research and development, manufacturing, and sales related to new technologies by establishing a management team with relevant knowledge and experience. The Board has been actively exploring other business opportunities to diversify the existing businesses of the Group and open up new markets with significant growth potential. In view of the rapid growth and increasingly widespread commercial application of artificial intelligence technology across industries globally, the Board believes this will provide the Group with opportunities to broaden its revenue sources and is therefore in the overall interest of the Company and our shareholders.
2 h ago
Could Jensen Huang Return to His Post? Silicon Valley Allies Pressure NVIDIA Corporation (NVDA.US) Board, While Bessent Calls for Major Leadership Reshuffle
According to reports, Jensen Huang is considering returning to NVIDIA as chief executive officer. Meanwhile, his Silicon Valley allies are pressuring NVIDIA's board to reinstate him.
2 h ago
EVEREST MED (01952): Velsipity and Igar successfully included in the 2026 edition of the National Reimbursement Drug List
EVEREST MED (01952) announced that Velsipity (etrasimod arginine tablets) and Igar (eravacycline hydrochloride for injection) have successfully been included for the first time in the new edition of the National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2026) (the new edition of the National Reimbursement Drug List) through national medical insurance negotiations. This medical insurance inclusion will further enhance the accessibility and affordability of Velsipity and Igar, giving more patients the opportunity to benefit from innovative treatments. The new edition of the National Reimbursement Drug List will officially take effect on January 1, 2027. Meanwhile, Nefecon (budesonide enteric-coated capsules) will remain on the National Reimbursement Drug List.
2 h ago
ASCENTAGE (06855): ASCENTAGE's Lishengto successfully included in the 2026 National Reimbursement Drug List; Nailike contract renewed
Ascentage Pharma (06855) announced that two of the Company's first-in-class innovative drugs have been successfully included in the new edition of the "National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2026)" (National Reimbursement Drug List), namely:
2 h ago
Jensen Huang Falls, Amodei Rises: Anthropic Orders Nearly 7x Oversubscribed, Wall Street Bets That "Those Who Sell the Shovels" Can Also Make Money
While Nvidia's Jensen Huang is experiencing a dramatic fall, one of the most important users of his company's chips is preparing to join the top tier of U.S. listed companieswith what is expected to be the largest IPO in history.
2 h ago
SIMCERE PHARMA (02096): Xianbixin Sublingual Tablets Included in the New National Reimbursement Drug List
SIMCERE PHARMA (02096) announced that on November 14, 2026, Xianbixin Sublingual Tablets (Edaravone and Dexborneol Sublingual Tablets) have been officially included in the "National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2026)" issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, and will take effect from January 1, 2027. In addition, Xianbixin Injection successfully completed its third medical insurance renewal.
2 h ago
Schmid: Inflation is "moving in the wrong direction," and the Fed has more work to do.
Schmid said on Sunday that inflation remains too hot and policymakers have more work to do.
2 h ago
CANBRIDGE-B (01228): Goruining and Mairebi Included in the First Edition of the Commercial Health Insurance Drug Coverage Cost List
CANBRIDGE-B (01228) announced that Goruining (velaglucerase beta for injection) (Goruining) and Mairebi (maralixibat oral solution) (Mairebi) have been included in the cost list published by the China Association of Actuaries on November 10, 2026. The cost list covers 117 drugs across multiple therapeutic areas including oncology, rare diseases, and chronic diseases, and is intended to solidify the pricing foundation for innovative drug coverage. Both Goruining and Mairebi were selected for the cost list, covering three rare disease indications respectively: Gaucher disease, and Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). They are expected to help reduce the medication burden for the rare disease community through commercial insurance channels.
3 h ago
Market News: Jensen Huang discussed with allies the matter of returning to NVIDIA to serve as CEO.
Latest news
6 h ago
U.S. Treasury Secretary Bessent said that Nvidia (NVDA.O) leadership needs a major overhaul after Jensen Huang was removed from his position. Bessent said that given the successive allegations against Nvidia, the company should consider looking externally for new leadership. He said: "That leads me to believe that the board, in its search for new leadership, should look outside the company. They need a major overhaul of leadership." Bessent also said he wants to know whether Nvidia deliberately ignored warning signs about shell companies. Bessent said: "What I always want to press on is, what kind of corporate culture exists inside Nvidia? Did they actively push these seemingly illegal sales transactions in order to inflate revenue and profit?" He added: "I believe the board and outside legal counsel need to provide answers within the next 10 days."
Latest news
9 h ago
Bessent: Expects inflation to fall significantly next month, calls on Fed to look ahead
US Treasury Secretary Bessent made a series of remarks on the current economic situation. On inflation, he noted that core inflation remains moderate and is already close to the Federal Reserve's target, and he expects the inflation rate to drop significantly next month. Regarding monetary policy, Bessent warned the Fed against further tightening and called on it to "look forward rather than dwell on the past." He said that both President Trump and he are fully confident in Fed Chair Warsh's fulfillment of the dual mandate. In addition, Bessent also mentioned the economic pressure policy on Iran, saying it "is working," and predicted that Iran will face a difficult winter due to natural gas shortages.
Latest news
9 h ago
NEW WORLD DEV (00017) rights issue to raise approximately HK$25 billion; CHOW TAI FOOK Enterprises, together with HSBC and DBS Bank, fully underwrites, demonstrating confidence.
NEW WORLD DEV (00017) announced today that the company proposes to conduct a fully underwritten rights issue to raise approximately HK$25 billion (before expenses). This proposed rights issue is one part of the group's comprehensive capital restructuring plan, a "combined punch" of measures.
10 h ago
BofA's Hartnett: Strong dollar hits global liquidity, risk assets remain difficult to enter for now, turning point postponed to next spring
BofA's chief strategist Hartnett maintains a risk-off stance and has postponed the entry window to next spring. The dollar index hit a new high for the year, and combined with high oil prices and stubborn inflation, all three of his entry conditions have failed to materialize.
11 h ago
China Securities Co., Ltd.: The end of October can be viewed as a reference for short-term bottom support for the market; focus on valuation switching at year-end.
The late-October low is highly likely to have been the bottom for this market cycle. AIAE indicates valuations are low, and November marks the starting point of a recovery, though the pace is more likely to be "two steps forward, one step back," with the slope of the recovery still subject to certain constraints.
12 h ago
Expectations of dollar tightening may have peaked: the peak of AI's boost to the US economy is passing, and a weak dollar will reopen room for China's non-AI assets.
Expectations of U.S. dollar tightening may have peaked: AI's boost to the U.S. economy is past its high point, and a weak dollar will reopen room for China's non-AI assets Judging from the new leasing commitment indicator of large cloud vendors, which leads U.S. economic growth and the job market, the boost from AI infrastructure to U.S. employment and economic growth may both slow in the fourth quarter.
12 h ago
In the past year alone, there have been 3 liquidation events exceeding US$1 billion! Bitcoin can aptly be called a "wealth destruction machine."
According to Coinglass data, over the past year, there were 13 instances of single-day liquidations exceeding US$500 million, 3 of which exceeded US$1 billion. This means that on average, less than once a month, the market experiences severe volatility sufficient to wipe out a large number of leveraged positions.
13 h ago
The "avoid institutional stocks" strategy may only have six months left: CITIC judges that large-cap stocks will outperform small caps next year, with early 2027 being the window to position
It is expected that during this round of adjustment, institutional large-cap stocks will be cleared out much faster than in the past, while the slow clearing process for micro- and small-cap stocks may have only just begun.
13 h ago
Memory is diverging: BofA says DRAM remains firm, while NAND has quietly weakened.
BofA believes the price-increase logic for DRAM has not yet been broken, while NAND spot prices have clearly loosened and will become the first product in this memory upcycle that needs to be repriced.
14 h ago
ORANGE TOUR (08627) Signs Business Cooperation Agreement with Hong Kong Niuyouguo
ORANGE TOUR (08627) announced that on November 11, 2026, the company's wholly-owned subsidiary Wuxi Orange Tour Cultural and Creative Co., Ltd. signed a business cooperation agreement with Hong Kong Niuyouguo Information Technology Co., Ltd., pursuant to which Wuxi Orange Tour and Hong Kong Niuyouguo agreed to carry out comprehensive cooperation in the following aspects.
14 h ago
Jiangsu Hengrui Pharmaceuticals (01276): Certain products included in the 2026 National Medical Insurance Catalog
Jiangsu Hengrui Pharmaceuticals (01276) announced that certain of the Company's products have been included in the 2026 National Medical Insurance Catalog.
14 h ago
HANSOH PHARMA (03692): Almonertinib Marketing Authorization Receives Positive Opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use
HANSOH PHARMA (03692) announced that on November 12, 2026, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a marketing authorization for almonertinib for the treatment of non-small cell lung cancer.
14 h ago
HANSOH PHARMA (03692): All approved indications of its marketed innovative drugs have been included in the medical insurance catalog.
HANSOH PHARMA (03692) announced that one additional indication for the Group's innovative drug Ameile and two additional indications for Xinyue have been successfully included in the new edition of the National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2026). The new national catalog will be officially implemented on January 1, 2027.
14 h ago
SUNSHINE PHARMA (06887): Ologlitazin Capsules Successfully Included in the 2026 Edition of the National Reimbursement Drug List
SUNSHINE PHARMA (06887) announced that recently, the Group's independently developed sodium-glucose cotransporter 2 inhibitor (SGLT-2 inhibitor), a Class 1 innovative drug Ologlitazin Capsules (trade name: Dongzean), has been successfully included in the latest edition of the "National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2026)" published by China's National Healthcare Security Administration. The 2026 edition of the National Reimbursement Drug List will be officially implemented starting from January 1, 2027.
14 h ago
XUANZHUBIO-B(02575): New indication for pirfenidone? NoPyroxasertib? Let me "" = piroxasertib? Actually it's "" (Piroxasertib?) Hmm. Let me just transliterate as "Piroxasertib" but safer: "Pyroxasertib"? The drug name is likely "Piroxasertib" (not standard). I'll render as "Piroxasertib." XUANZHUBIO-B(02575): New indication of Piroxasertib included in the 2026 National Basic Medical Insurance Drug Catalog
XUANZHUBIO-B(02575) announced that the new indication for its self-developed innovative drug Piroxasertib tablets, in combination with an aromatase inhibitor (AI) for the first-line treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, has been included in the National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug Catalog (2026). The 2026 National Basic Medical Insurance Drug Catalog will be officially implemented starting January 1, 2027. As of the date of this announcement, all three indications approved in mainland China for Piroxasertib have been included in the National Basic Medical Insurance Drug Catalog.
14 h ago
GRAND PHARMA (00512) Builds a Dual-Line Payment Framework of Medical Insurance + Commercial Insurance: Yigantai Opens Up Commercial Insurance Payment Channels, Laiteling Included in the National Medical Insurance Drug Catalog for the First Time, and Multiple Chronic Disease Pipelines Continue to Expand Volume on the Back of Medical Insurance
Against the backdrop of accelerating development of the multi-tiered medical security system, Grand Pharma (00512) is stepping up its "medical insurance + commercial insurance" dual payment channel layout.
14 h ago
HENLIUS (02696): New Indications for HANSIZHUANG and Futanning Included in the National Reimbursement Drug List
HENLIUS (02696) announced that recently, HANSIZHUANG (serplulimab injection) was included in the Class B scope of the "National Drug Catalog for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance (2026)" for the first time, and the included indications cover all indications approved for marketing in China (excluding Hong Kong, Macao, and Taiwan, the same below). In addition, Futanning (voruciclib citrate capsules) had its second indication newly included in the National Reimbursement Drug List. The new version of the National Reimbursement Drug List will officially take effect on January 1, 2027.
14 h ago
INNOVENT BIO (01801): Seven innovative products, including Xin'ermei and Xinmeiyue, successfully included in the 2026 edition of the National Reimbursement Drug List
Innovent Biologics (01801) announced that seven innovative products from Innovent Biologics have been successfully included in the new edition of the National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2026).
14 h ago
JW THERAP-B (02126): Carteyva (relma-cel injection) included in the National Basic Medical Insurance Drug Catalog
JW THERAP-B (02126) announced that the company's core product Carteyva (relma-cel injection) has been officially included in the 2026 version of the National Reimbursement Drug List (NRDL). Starting from January 1, 2027, patients who fall within the national medical insurance payment scope can receive basic medical insurance reimbursement for Carteyva as stipulated. This medical insurance payment scope covers all three approved indications of Carteyva, including large B-cell lymphoma (LBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The price of Carteyva upon inclusion in the National Reimbursement Drug List is RMB288,600.
14 h ago
LUYE PHARMA (02186): Ruoxinlin successfully renewed in the National Reimbursement Drug List
LUYE PHARMA (02186) announced that Ruoxinlin (Toludesvenlafaxine Hydrochloride Extended-Release Tablets), a Class 1 innovative drug, has successfully been renewed on the "National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2026)" (the 2026 National Reimbursement Drug List) for the treatment of depression.
14 h ago
Shanghai Fosun Pharmaceutical (02196): Multiple products newly included in the National Reimbursement Drug List
Shanghai Fosun Pharmaceutical (02196) announced that, according to the "National Drug List for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2026)" issued on November 14, 2026 by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, multiple marketed products of the group have been included for the first time, had remarks-related information adjusted, or been transferred from negotiated drugs to routine list management.
15 h ago
PEGBIO CO-B (02565)'s core product Peidakang (pegmivalapenta injection) has been successfully included in the 2026 National Reimbursement Drug List.
PEGBIO CO-B (02565) announced that the Group's independently developed core innovative drug product pegmivalapenta injection (trade name: Peidakang, hereinafter referred to as "Peidakang") has been successfully included in the "2026 National Drug Catalog for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance" newly released by the National Healthcare Security Administration.
15 h ago
GRAND PHARMA (00512): Six Products Successfully Included in the 2026 National Reimbursement Drug List, the Commercial Insurance Innovative Drug Catalog, and Industry Supporting Lists
GRAND PHARMA (00512) announced that recently, a total of six products of the Group were successfully included in the "National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug Catalog (2026)" and the "Commercial Health Insurance Innovative Drug Catalog (2026)" issued by the National Healthcare Security Administration of the People's Republic of China (NHSA), the "Recommended List of Drugs Covered by Commercial Health Insurance (First Edition)" issued by the Insurance Association of China, or the "Drugs Involved in the Calculation of Commercial Health Insurance Coverage Costs" issued by the China Association of Actuaries.
15 h ago
Bitcoin breaks above $66,000, up 2.92% intraday.
Latest news
16 h ago
GF SEC: How should we view Nasdaq's 23-hour trading?
U.S. stocks already have trading instruments covering Asian hours, and it is expected that extended U.S. trading hours will not have a substantial impact on A/H share trading.
16 h ago
AI capex peaking = the dollar peaking? Goldman Sachs 2027 outlook: the dollar is about to see its "last rally"
Goldman Sachs believes the dollar still has room to rise in the short term, but a substantial reversal will come in 2027.
16 h ago
Shenwan Hongyuan Group: How much longer can the chip "shortage" last?
The chip shortage index leads consumer electronics CPI in South Korea and Taiwan, China by more than half a year. This means that even if the chip shortage begins to ease, upward pressure on consumer electronics prices may persist until 2027.
17 h ago
From "selling subscriptions" to "selling outcomes": Adobe (ADBE.US) tests weekly billing for Acrobat, BTIG says growth sustainability remains to be verified
At last week's MAX conference, Adobe unveiled new Agentic AI tools and previewed native MCP (Model Context Protocol) integration, allowing creators to directly invoke third-party agents within Photoshop, Illustrator, Premiere, and After Effects.
17 h ago
EB SECURITIES: Market-based New Energy Power Generation Sets Sail; Industry Incremental Structure Will Shift to Overseas Wind Power and Energy Storage
Over the next three years, global demand for new energy will continue to grow, but the incremental structure will shift from high-base expansion in the domestic market to overseas wind power and energy storage.
17 h ago
1
2
3
4
5
1158
Latest
3 m ago
Jinjing New Energy (01783.HK) Secures Another Locked-In Card Signing, Strengthening the Compliant Computing Power Leasing Logic
4 m ago
A strong dollar, high oil prices, and persistently elevated inflation together form a triple pressure, and gold has once again pulled back, with the move in line with our expectations. On the oil front, Iran is still intermittently attacking tankers passing through the Strait of Hormuz that are not under its control, and the decline in oil prices has slowed; Federal Reserve Governor Waller has signaled a 50-basis-point rate hike in December, and Goldman Sachs has already incorporated a March rate hike into its baseline forecast; the 10-year U.S. Treasury yield has once again risen above 5%, and the current environment of high interest rates and a strong dollar is unfavorable for dollar liquidity and clearly unfavorable for gold's trajectory as well.
8 m ago
Strategy's US after-hours trading fell over 8% as the company was removed from the MSCI index, effective after the close on November 30.
10 m ago
Morgan Stanley Raises South Korea's Terminal Rate Forecast; Tightening Cycle May Extend to 2028
11 m ago
Former Party Secretary of Xinjiang Medical University Gao Fashui under investigation
See all latest
Seeking Coverage
Being Writer
Exploring Cooperation